Onkológia 5/2019
Brachytherapy in prostate cancer
Interstitial brachytherapy has been standard treatment option of localized prostate cancer for several decades. Brachytherapy allows to deliver ablative dose of radiation to the tumour volume with great potential of sparing surrounding critical structures (rapid fall-off in radiation dose). Mature data show, that brachytherapy results in consistently high local control rates, high disease-free survival and low risk of long-term morbidity. Ultrasound guided permanent implantation (low dose rate, LDR) is treatment option in low and intermediate risk prostate cancer as monotherapy or in high risk as combination with external beam radiotherapy as a boost. High dose rate (HDR) brachytherapy is a logical consequence of modern technological development with implementation in prostate cancer, but supported by the guidelines only as a boost after external beam radiotherapy in intermediate and high risk prostate cancer, or as salvage therapy.
Keywords: prostate carcinoma, brachytherapy, LDR, HDR, treatment
